2006 No difference 2019 Enormous difference Today the products have little similarity. Arch spent an enormous sum to perfect the MIT technology and now has over 50 patents to itself. FDA approval in December 2018 was Arch's confirmation.

Polyphemus No they thought they had a 'better" mousetrap.

We all are going to have to rethink the business model of ARTH:

Closure employees numbered 75 at time of commercialization in 1999. Arch employees total 8 at time of commercialization in 2019. Arch has never had more than 8 employees.

What ARTH has pulled off when compared to Closure is simply amazing.

Until you do a deep dive you come to realize what they have pulled off.

So rather than doing a straight up IPO in 2013 and raising the $ 33.7 million that they raised thus far they elected to do a reverse merger with a warrant strategy that backfired when the stock price went down in stead of up.

This is in the Form 10-K

They were private from 2006 until 2013 where Norchi et al financed.

I have written about this in the past. This mess up created the opportunity that we have today and in the past. They should have done a clean IPO.

ARTH is following the marketing gameplan laid out by Closure Medical (1996-2004) when it was acquired by JNJ in early 2005.

The profit margins were very large and the marketing JV's lucrative for Closure with upfront fees. Closure's medical applications were narrow compared to ARTH.

Please tell ARTH:

Yahoo

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures.

ARTH Press release

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include AC5™ Topical Gel, AC5™, Topical Hemostat1 and AC5™ Surgical Hemostat.1

Only been public since May 20, 2013. Six years. Since May 20, 2013 have raised a total of $ 33,778,823 which is tiny in biotech world.

Per Norchi “premium pricing” on AC5 to reflect its best in class status- Normal is $ 200 to $1,500 per unit. Extremely low manufacturing cost.

They figured out the manufacturing side of the equation very early on. That was one of the very first assignments.

Arch has not been close to commercialization in the past four years.

Corporate Presentation

https://content.equisolve.net/archtherapeutics/media/c6dc3c52a4e0458fae43779086460ea0.pdf

$ARTH Presentation LD Micro 6/4/19 by Dr. Terry Norchi plus my comments

1) On verge of commercialization. How many of your biotech investment positions are in the same situation? What is the risk here?

2) Planned revenue stream by End of Year. Building AC5 Inventory now.  

 
3) Execute commercialization rollout and partnering strategy (in process now) 

4) Multiple Selling Partner Strategy. Great news that there will be a different mix of partners between Europe and United States. Means there will be multiple partners and news announcements and possible up-front fees. This also means ARTH will be around for a while and not be acquired. Thus this will maximize ultimate buyout price. Intellectual property is now beyond FIFTY (50) patents. Big Positive. 

5) Also mentioned significant interest out of Asia

6) Hired VP of development Dermal Applications (Wadsworth with deep ties to wound care space)  to handle all the possible joint venture situations. 

7) Mentioned focusing on Military opportunity for use of AC5 

8) CE Mark should be any day now 

9) Broad US (510 (k)) FDA clearance for external applications of AC5. Large external applications.   

10) Submit clinical study IDE pre-submission for biosurgery--$6 $7 billion market opportunity   

11) Cash burn is $ 1.9 million per quarter. Have approximately $ 4.2 million of cash.   

12) 27,796,019 warrants outstanding with total exercise price of $ 18,0541101   8.9 million warrants at $ .25 share (in the money now) 

13) Total Capital raised by ARTH since inception $ 33,778,723. Tiny !!!!!!!!!!!!!!!!!!!!!!!! The warrants are $ 18,054,101 or  53% of the total capital raised.

14) Even at the depressed market price --for every $ 1 raised by $ARTH it is worth approximately $ 1.72. Amazing.

15) Closure Medical Acquired by JNJ 2005 (comparable to ARTH---except ARTH has 10 times intellectual propery) $ 370 million. Market Cap of ARTH fully diluted is only $58 million or only 16 % of the $ 370 million.

To get to $ 370 million ARTH would have to equal $ 1.71 per share.

Presentation is here: http://wsw.com/webcast/ldmicro16/register.aspx?conf=ldmicro16&page=arth&url=http://wsw.com/webcast/ldmicro16/arth/index.aspx

Planned revenue by end of Year. Multiple partners. Possible up front fees.

27,796,019 warrants outstanding with total exercise price $ 18,054,101

8.9 million warrants at $ .25 share

LOL Total capital raised by ARTH since inception $ 33,778,723 (TINY !!!!)


Even at the depressed market price --for every $ 1 raised it is worth approximately $ 1.72. Amazing.

Closure Medical Acquired by JNJ 2005 (comparable to ARTH---except ARTH has 10 times intellectual propery) $ 370 million

Market Cap of ARTH fully diluted is only $58 million or only 16 % of the $ 370 million.

To get to $ 370 million ARTH would have to equal $ 1.71 per share.

On verge of commercialization.

Great news that there will be a different mix of partners between Europe and US.

Also mentioned strong interest Asia.

Means we will have multiple partners and news announcements.

Also means ARTH will be around for a while.

I was afraid they would partner with just one.

Exactly what is the risk here???

Have you ever seen a liquid being classified as a medical device?


Well that is what Arch's AC5 is.

"Arch's first product stops bleeding in seconds as opposed to competitor products in minutes even in the presence of anticoagulants something that competing products cannot do.


Arch's AC5 is A LIQUID noncoagulant homostatic agent classified as a MEDICAL DEVICE."

Watch the Roth presentation on Arch's website.

https://www.archtherapeutics.com/

Daniel L. Kapp MD Chief of Surgery, Palm Beach Gardens Medical Center

Board Certified Plastic Surgeon

Director Jupiter Wound Care

www.drdanielkapp.com/meet-dr-kapp.php

"The video illustrates the use of AC5TM Topical Gel in porcine surgical wound models of a skin graft (harvest and placement) and of incisions made in the presence of the anticoagulant heparin. Dr. Daniel Kapp, Chief of Plastic Surgery at Palm Beach Gardens Medical Center and advisor to Arch, performed the demonstrations and narrated the video." 


https://ir.archtherapeutics.com/presentations/view/28/demonstration-of-ac5-topical-gel-in-porcine-full-thickness-surgical-wound-models

Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical GelAC5™ provides a new option for the treatment of topical wounds


FRAMINGHAM, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the 510(k) premarket notification for AC5™ Topical Gel has been reviewed and cleared by the U.S. Food and Drug Administration (FDA), allowing for the product to be marketed. AC5 Topical Gel is a topical dressing indicated for use in the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds.

This is a clean public shell that I believe is held by few shareholders and in which a reverse merger can occur.

The great thing is there are many non-FDA products. More to come.

Thanks. What do you think about Microsoft Health wearable program?

Is Know Labs even followed in Seattle?

Doing due diligence on the major shareholders and officers of Know Labs

Analyzing Ownership
Shares Outstanding 17,531,522

Ownership breakdown
Directors and Officers

Ronald P. Erickson 7,889,015 32.6 %
Philip A Bosua 2,917,500 16.6
Jon Pepper 238,000 1.4
Ichiro Takesako 150,000 .9
William A Owens 650,000 3.7
_______ ____
11,844,515 67.6

Clayton Struve 800,000 4.6

Public 4,887,007 27.8%
_______ ____
Total 17,531,522 100.00

Fully Diluted Shares Outstanding 49,121,923

Shares Outstanding 17,531,522

Warrants Outstanding 15,473,398 at average price of $ .326

Employee Stock options 2,182,668 at average price of $ 1.70

Convertible Preferred Stock 4,914,071

Convertible Note Payable 9,020,264 at $ .25 share

Grand Total Fully Diluted Shares 49,121,923

Break Down of major shareholders

Clayton A Struve 16,763,790 34%
Ronald P Erickson 7,889,015 16%
Philip A Bosua 2,917,500 6%
Dale Broadrick 2,226,036 4.5%

Total 29,796,341 61%


1) Backgrounds of major shareholders of Know Labs, Inc.-note experience of holders—Note successes

Clayton Struve

https://tinyurl.com/y966lxym

Mr. Clayton A. Struve, Clay has been Partner of CSS LLC, a Proprietary Trading Firm since September 1998. From October 1997 to joining CSS LLC, Mr. Struve pursued personal investment activities.

From January 1991 to October 1997, Mr. Struve served as Managing Director of Swiss Bank Corporation, holding various positions, including co-head of equities and co-head of Global Risk Control.

From 1981 to 1991, Mr. Struve served as Partner at O'Connor & Associates and served Head Of Equities, Head Of Risk and Head of New Products. He also directed development of risk modeling and systems. He has been Director of Peak6 Investment, LP (Alternate name: Peak6 Corp.), since March 2001. Mr. Struve also serves as a Member of the board of directors of O'Connor Partnerships, a Private Investment Firm.

He serves on the boards of Target Discovery Inc., a Biotechnology Firm, and Prediction Cos. LLC, a Quantitative Trading Advisory Firm. Mr. Struve holds a BS in Management and Finance from Massachusetts Institute of Technology.

Ron Erickson-attorney and venture capitalist

https://en.wikipedia.org/wiki/Ron_Erickson_(investor)

Ron Erickson (born December 24, 1943, Tacoma, Washington) is an American business executive, lawyer, and angel investor based in Seattle. After co-founding Microrim in 1981,[2] he has either founded or served as an executive for companies such as GlobalTel Resources, Inc.,[2] GlobalVision, Inc,[1][3] Egghead Software, Inc.,[2] and Blue Frog Media. He was the sole investor in Double Down Interactive, a social video game studio[4] that was sold for up to $500 million in 2012.

Early in his career Erickson worked in public policy at the White House and the Office of Economic Opportunity in Washington, D.C.,[7] becoming the latter's Branch Chief for Emergency Food and Medical Services.[1] He also worked for the Rockefeller Commission on Critical Choices in New York City.[7]

He studied law at the University of California at Davis, graduating with a Juris Doctor,[ and is licensed to practice law through the Washington State Bar Association.He has worked in Seattle at firms such as Kargianis, Austin & Erickson, and Ronald P. Erickson & Associates.

Philip Bosua –approximately 45 years old

Company CEO 4/10/18 Chief product officer since 7/7/17 From 9/12 to 2/15 CEO of LIFX, Inc--still owns 9%

Philip Bosua Linked in
https://www.linkedin.com/in/philbosua/

Bosua has had previous success at Kickstarter in 2014- in other words this is not his first rodeo at Kickstarter.

Bright idea: Australian Phil Bosua raises $US12m as he readies smart light switch

https://tinyurl.com/yb92c6st

After a hugely successful Kickstarter campaign, LIFX secures $12M for its smart light bulbs

https://startupbeat.com/lifx-secures-12m-id3859/13019/
https://www.lifx.com.au/pages/about

“Back in 2012, when a smart home was just whispers and dreams, we kickstarted into action and launched the first ever multicolored LED Wi-Fi light. Its been a crazy 5 years and we now offer 12 products in over 80 countries that bring the future of lighting within your control.
Oh, and we’ve made some friends along the way. Like any good smart home product, LIFX works seamlessly with other industry leaders such as Amazon Alexa, Nest & Google Home. You can check out the full range here.”

“Leaders in Wi-Fi connected smart lights.”

“The San Francisco– and Melbourne-based startup launched in 2012 with a $1.3 million Kickstarter crowdfunding raise. It was founded by CEO Phil Bosua, CTO Marc Alexander, Guy King, Jake Lawton, CIO Daniel May and Bevan Clark.”

2) Chief Medical Officer

James Anderson, MD, has joined the Company as Medical Director in September 2018

James H. Anderson, Jr., M.D., FFPM, FACE, is a diabetologist and endocrinologist.

Dr. Anderson previously joined Eli Lilly and Company (LLY) where he was responsible for Lilly’s global clinical diabetes development program. He managed diabetes and cardiometabolic drug clinical development, and drove the clinical development of three families of billion dollar diabetes care products.

What are you hearing of the status of the private placement? With market price about double the private placement price it would seem to be very attractive.

Thanks for your posting.

Have you seen the new office for Phil et. al.? Very nice.

So they want to do $5 million in KickStarter for Calorie Counter

At $ 99 that is only just over 50,000 people

Seems like there would be a lot more people in WeightWatchers and Diet Fads interested in this?

This product could go viral?

Have you met Clayton Struve--He is largest shareholder owning 34% of Fully Diluted shares

What is the fully diluted shares outstanding? 49,121,923

BTW hear the FlashFunder shares will be $ 1.

No product?

ARTH: All Aboard! Next Stop AC5 510k Decision


https://tinyurl.com/ycut7397

$ARTH Elevator Pitch

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135879162

Per yesterday's conference the product lines of ARTH have expanded immensely since when this elevator pitch was drafted last year.

Intellectual property has also expanded.

AC5 is a clear liquid classified as a medical device. How is that possible? AC5 when applied has no metabolic or body interaction and acts merely as a physical mechanical barrier.
 
AC5 is a noncoagulant hemostatic agent. There are no other noncoagulant hemostasis agents on the market. Thus AC5 works in the presence of BLOOD THINNERS! Only one that does.
 
The clear liquid stops bleeding in SECONDS compared to minutes for most of the product’s competitors.
 
   There are many other hemostatic agents, but:

They all rely on using the patient's blood,

*They all take minutes to stop bleeding, not seconds


*None of them create a clear seal that a surgeon can see through


* None of them work just as well on people on blood thinners

* None of them work in every situation where bleeding has to be stopped

2019 IPO CRM Heelo www.heelocoupons.com/index.html Windstar thank you on FUSZ and Heelo

Bono Rock CreeK? Thanks

ARTH will never reach your expectation. It will be bought out based upon its intellectual property. Study Closure Medical being Acquired by JNJ 2005
for $370 million. ARTH's market cap is only 29% of that.

Norchi can arrange any financing needed in less than 24 hour notice. A complete cakewalk. They are lined up and ready. $ARTH's intellectual property is unmatched---FIFTY (50) PATENTS ------

$ARTH Arch Therapeutics CEO looks ahead to positive results on AC5 gel http://tinyurl.com/ydco3az3 ;
 
Similar risk profile Diamedica  DMCAF
 
Diamedica Capital Analyzed 

https://tinyurl.com/y8m3a5nc

Techpool Bio-pharma sale and impact on DMCAF

https://tinyurl.com/ycp9p76v



Patrick Cox Email DMCAF—John Mauldin Investor 

https://tinyurl.com/y7os2fzl

Sale of Competitor Product establishing Value for DMCAF

https://tinyurl.com/y7uqcxsc



Actual Zacks Initiation Report

https://tinyurl.com/ycklvszh

TooTallJones Hey good to see you. We met in Mexico. Remember?

“The compound is used in Asia for an astonishing list of diseases, despite the fact that it’s extremely expensive.

The Asian form is also suboptimal as a Western drug candidate because it comes from pig pancreases and the urine of young humans. Using animal or urine sources is not just aesthetically distasteful, it introduces risks of contamination into the production process that tend to put off regulators.

DiaMedica solved that problem by developing a proprietary, genetically modified cell type that expresses enormous amounts of KLK1 at a fraction of the cost of existing cell technologies. Big Pharma had tried to do this for years, always failing.

These cells have allowed DiaMedica to synthesize a drug under standardized conditions that has enormous potential—not only as treatments for many diseases, but as a breakthrough anti-aging geroprotector”



“Think of recombinant tissue kallikrein, DiaMedica’s lead product, as being a blood-vessel opening, blood-flow promoting substance that is nature’s preferred way of enhancing perfusion (flow) in tissues. You don’t have to be a rocket scientist to think of disease states where flow is aberrant or altered or needs assistance, right? What if recombinant tissue kallikrein had a role in all or many of those settings? Stroke, heart attack, peripheral vascular disease, angina, hypertension, maybe even PULMONARY hypertension.”

John Mauldin’s Biotech company -- DiaMedica (TSXV:DMA; OTCQB:DMCAF)

Compound is blood vessel opening, blood flow promoting substance used in many situations but especially those suffering a stroke. A total of 40 published clinical studies.

Compound used in Asia coming from pig pancreases and urine from young humans at very high cost.

Diamedica’s improved the compound with a synthetic version at a fraction of the cost.



Mauldin Economics write-up https://tinyurl.com/yao9dl9d

DD Thanks for all your due diligence and work on this.

So it looks like they will distribute 100% of their position in AGEX to obtain tax free distribution.

Billionaire Jim Mellon might be talking about at his conference this weekend in Britian. He mentioned last year because of interest in longevity companies. When Mellon gets interested in an area he writes a book. Juvenescence is the book. I will dig up his presentation last year.

Enjoy this:

https://www.dropbox.com/s/a2kqss0b9cwxdc5/BTX%2002-02-2018%20Initiation.pdf?dl=0

Question DD How long have you owned? Did you receive previous distributions? What part of BTX interests you the most?

I was following Geron (GERN) many years ago. Amazing that the IP landed in AgeX . So the 10 million raised for AgeX was done at a valuation of $ 66 million. I estimate that BTX shareholders will receive about .20 AGEX shares for each BTX share.

Which Billionaire Randall Kirk Biotech company is the most capital efficient based upon market cap? $HALO by a mile.


ZIOPHARM Oncology, Inc. $ZIOP) Capital Raised since inception $ 619.232 million Market Cap $ 607.5 million

For every dollar ZIOP has raised in capital it has resulted in $.98 of Market Cap

Randall Kirk and affiliates owns 7.4% of ZIOP times $ 607.5 Million ZIOP market cap or $ 44.9 Million

Halozyme Therapeutics, Inc. (HALO) Capital Raised since inception $ 718.553 million Market Cap $ 2.63845 Billion

For every dollar HALO has raised in capital it has resulted in $3.66 of Market Cap

Randall Kirk and affiliates owns 18.5% of HALO times $ 2.638 Billion HALO market cap or $ 488 Million---10 TIMES the ownership of ZIOP !!

Intrexon Corporation (XON) Capital Raised since inception $ 1.370 Billion Market Cap $ 1.509 Billion

For every dollar XON has raised in capital it has resulted in $1.10 of Market Cap

Randall Kirk and affiliates owns 52.1% of XON times $ 1.370 Billion XON market cap or $ 713.8 Million

Which Kirk Biotech is likely to be acquired first: $HALO--

$HALO Tweets following science https://twitter.com/fezziwig2008

Once again a ton of misinformation. This person is going all over the internet and refuses to talk with Dr. Terry Norchi.

He claims his information comes from the FDA. The people he spoke to are not relevant people pertaining to ARTH. He talked to a person who picked up the phone. He has listed FDA names he has talked to so those are being reviewed. Since all ARTH relevant FDA personnel and related information are confidential any relevant FDA person talking to him would be fired.

Roth analyst Michael Higgins joined a new firm. Ladenburg. This person is dreaming.

ARTH as disclosed got a new communication with questions last week. MDUFA clock did not allow for extension.

Dr. KSS wrote a short column on all this over a week ago.

Hilarious !!!!!!!!!!!!!!! So the FDA is talking to Zipppp about Arch. Need to report this to FDA?

Zippp who exactly did you talk to and when?

Who exactly did you talk to at the company?

Not seen so much nonsense since 2015.

Well the answer to that it is very difficult to purchase this stock. We have been told that a small group controls over 70% I believe the number thrown out by Bono some time.

I reviewed the last balance sheet of company and summarized my findings. To me it was doable to get out of Chapter 7 because most of the liabilities were payroll related.

Normal Chapter 7 is within 12 months. Where is Bono???? I think there is a whole lot going on. I am so happy to see Anatabloc back on the market. There is a chance the Department of Defense will bring it back here also.

Surprised that Anatabloc in capsule form are not time release. They were working on that forever. That would be a game changer. I guess they could change to that.

$HALO

Which Billionaire Randall Kirk Biotech company is the most capital efficient based upon market cap? $HALO by a mile.

ZIOPHARM Oncology, Inc. ($ZIOP) Capital Raised since inception $ 619.232 million Market Cap $ 607.5 million

For every dollar ZIOP has raised in capital it has resulted in $.98 of Market Cap

Randall Kirk and affiliates owns 7.4% of ZIOP times $ 607.5 Million ZIOP market cap or $ 44.9 Million

Halozyme Therapeutics, Inc. (HALO) Capital Raised since inception $ 718.553 million Market Cap $ 2.63845 Billion

For every dollar HALO has raised in capital it has resulted in $3.66 of Market Cap

Randall Kirk and affiliates owns 18.5% of HALO times $ 2.638 Billion HALO market cap or $ 488 Million---10 TIMES the ownership of ZIOP !!

Intrexon Corporation (XON) Capital Raised since inception $ 1.370 Billion Market Cap $ 1.509 Billion

For every dollar XON has raised in capital it has resulted in $1.10 of Market Cap

Randall Kirk and affiliates owns 52.1% of XON times $ 1.370 Billion XON market cap or $ 713.8 Million

Which Kirk Biotech is likely to be acquired first: $HALO--

$HALO Tweets following science https://twitter.com/fezziwig2008

$HALO Tweets following science https://twitter.com/fezziwig2008

Thank you. I have been interested in the persuasion and Dilbert commic strip Scott Adams is a professional persuader. He is on twitter. I bring this up based upon what you do for a living. I have just finished reading his book Win Bigly.

Thinks I never thought about. So there is also a master persuader out there that has written several books:

https://www.amazon.com/gp/product/150822319X/ref=oh_aui_detailpage_o00_s00?ie=UTF8&psc=1

Imagine being a litigator and being armed with this !!

Regards

Anatabloc is coming back via the Department of Defense !!!!!!!!!!

“House passes DoD bill with room to renegotiate drug, device approval provision”

The US House of Representatives this week passed a nearly $700 billion defense policy bill, but left room for negotiating new terms related to a controversial provision which would have given the Dept. of Defense the power to approve medical devices and drugs without FDA clearance.[...]

http://www.massdevice.com/house-passes-dod-bill-room-renegotiate-drug-device-approval-provision/